Skip to content
Summer 2026 · 26% off every plan with SUMMER26 See pricing
Optionomics
NGVT · 10-Q filed May 7, 2026

NGVT earnings analysis

What we found in NGVT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.

Our reading of the filing · Free to read, no account needed

Ingevity Corporation's Q1 2026 results show significant outperformance with net sales of $258.0 million, up 4% from the prior year, and EPS of $1.15 eclipsing estimates of $0.83. However, while the Performance Materials segment drove revenue growth, the Performance Chemicals segment posted flat sales and declining EBITDA. The company faces ongoing challenges from legal costs and restructuring but maintains an optimistic outlook for the year.

What stood out

The parts that mattered.

Pulled out of the filing itself, with the figures the company reported.

Significant Revenue Growth
Net sales increased by 4% year-over-year to $258.0 million, up from $247.9 million in Q1 2025.
Strong EPS Beat
EPS reached $1.15, exceeding estimates of $0.83, marking a notable 38.55% surprise.
Performance Materials Robust Gain
The Performance Materials segment saw a 6% increase in net sales to $155.4 million, driven by pricing actions.
Declining Performance Chemicals Segment
Performance Chemicals reported flat sales at $58.3 million, with a 10% decline in Road Markings product line.
Improved Operating Margins
Gross margin improved to 45.1%, up from 45.0% in the prior year despite rising manufacturing costs.
Healthy Cash Flow from Investing Activities
Generates $106.3 million in cash from investing activities primarily driven by the sale of the industrial specialties product line.
What to watch

And the other side of it.

The offsets in the same document — the things a summary that only listed the good news would have left out.

Legal Settlement Expenses
Incurred a $113.2 million cash outlay due to the BASF litigation settlement, affecting operations and liquidity.
Ongoing Restructuring Costs
Anticipates indirect costs of $12-18 million from divested product lines impacting margins in 2026.
Volatile Commodity Costs
Rise in raw material costs could squeeze margins, highlighted by a 10% increase in natural gas prices affecting $1.0 million in costs.
The numbers

What they reported.

What the company itself reported, taken out of the document.

What survived to operating profit
Of every $100 of revenue Cost of sales $55 Operating expenses $33 Left as operating profit $12
Percentages of revenue, taken from the filing. Drawn this way because it holds whatever scale the company reports in.
Earnings per share
$1.15
Gross margin
45.1%
Operating margin
11.7%
Segment
Performance Materials
Segment
Performance Chemicals
Segment
Advanced Polymer Technologies
Guidance

What they said about what is next.

Management reaffirms the previously disclosed outlook for 2026, excluding contributions from divested product lines.

How we read the filing overall

The filing reads better than the one before it.

One reading of one document. It is not advice, and it is not a forecast.
Earlier filings

What came before.

10-K · February 26, 2026
Ingevity completed its Strategic Portfolio Review and closed the sale of the North Charleston CTO refinery and most of the industrial specialties product line (the Divestiture) on January 1, 2026, creating a simplified…
10-Q · May 6, 2025
Ingevity reported Q1 net sales of $284.0 million, down $56.1 million (-16.5%) from $340.1 million a year ago, but delivered a return to profitability with net income of $20.5 million and diluted EPS of $0.56 (versus a…
10-Q · October 30, 2024
Ingevity reported Q3 net sales of $376.9 million, down from $446.0 million a year earlier, and recorded a net loss of $107.2 million (diluted loss per share $2.95). Management took a non‑cash goodwill impairment of…
10-Q · August 1, 2024
Ingevity reported Q2 net sales of $390.6 million and GAAP diluted loss per share of $(7.81), missing consensus on both revenue and EPS. Results were materially affected by a $349.1 million non-cash goodwill impairment…

This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.

Read the next one first.

We read every filing NGVT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.

Cancel anytime · Month to month · Switch tiers whenever